15-min delayed · Sep 14, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Rapid Micro Biosystems Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $5.00 to $7.00, a moderate spread. The average target of $6.00 sits 410% above the current $1.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Rapid Micro Biosystems Inc.
As of Sep, 2 of 2 firms rate RPID a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RPID EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.18 – $-0.13 · 3 analysts · -44% YoY
Next period, 3 analysts expect Rapid Micro Biosystems Inc to earn $-0.16 a share (range $-0.18 – $-0.13), versus $-0.28 a year earlier. Full-year consensus is $-0.94, growing to $-0.73 the year after.
REVENUE · NEXT QUARTER
$13.3M
Range $12.3M – $15.1M · 3 analysts · +18% YoY
Revenue is expected to reach $13.3M (range $12.3M – $15.1M), +17.7% year-over-year. Full-year consensus is $39.3M, rising to $46.5M next year.
Top analysts covering Rapid Micro Biosystems Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RPID.
#1
TF
Thomas Flaten
Lake Street · Rank #242
Buy
$7.00+495.2% to target
Overall win rate
40%
+ Follow
#2
Paul Knight
Keybanc · Rank #349
Buy
$5.00+325.2% to target
Overall win rate
34%
+ Follow
#3
BS
Brendan Smith
TD Cowen
Buy
No targeton RPID
Coverage
—
+ Follow
RPID stock forecast FAQ
What is RPID's average 12-month price target?+
The 2 analysts with a live target average $6.00 for Rapid Micro Biosystems Inc over the next 12 months, ranging from a $7.00 high to a $5.00 low.
Is RPID stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RPID?+
The Street-high target is $7.00 (Lake Street), and the Street-low is $5.00 (Keybanc). The average of all 2 active targets is $6.00.
How many Wall Street analysts cover RPID?+
2 analysts have an active rating on Rapid Micro Biosystems Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RPID?+
Among analysts who currently cover RPID, Thomas Flaten of Lake Street has the strongest overall Quantellect track record (Rank #242). Their current call is Buy with a $7.00 target.
What is Rapid Micro Biosystems Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.18 – $-0.13) across 3 analysts. Full-year EPS is projected at $-0.94, rising to $-0.73 the following year.
How much revenue is Rapid Micro Biosystems Inc expected to report next quarter?+
Consensus revenue is $13.3M (range $12.3M – $15.1M). Full-year revenue is projected at $39.3M, growing to $46.5M next year.
Have analysts been upgrading or downgrading RPID lately?+
As of Sep, 2 of 2 firms rate RPID a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RPID calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
